Exelixis Inc. (EXEL) Breaks into New 52-Week High on March 18 Session

Equities Staff  |

Shares of Exelixis Inc. (EXEL) broke into a new 52-week high yesterday, hitting a peak of $25.31. Shares closed at $24.14 after opening at $24.70 for a move of -1.59%. The company now has a market cap of $7.25 billion.

Investors and traders can learn a lot about a stock’s momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out before an impending period of decline.

For Exelixis Inc., the new 52-week high came on volume of 5.19 million. The stock has a float of 300.13 million shares and average daily volume of $n/a. It has a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Exelixis Inc. now has a P/E ratio of 11.

For a complete fundamental analysis analysis of Exelixis Inc., check out Equities.com’s Stock Valuation Analysis report for EXEL.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma. The company has partnerships with larger pharmaceutical and biotech firms to develop its pipeline, including Bristol, Sanofi, and Merck.

Exelixis Inc. is based out of Alameda, CA and has some 484 employees. Its CEO is Michael M. Morrissey.

Exelixis Inc. is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

To get more information on Exelixis Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: EXEL’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

Blockchain in Healthcare - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Digital Health - How Blockchain technology can make health care systems more patient-centric and sustainable